Headache Disorder

Treatment with atogepant at 30 mg and 60 mg reduced mean monthly migraine days over 12 weeks compared with placebo, while showing good safety and tolerability profiles, according to research published in the Lancet Neurology.

Last week, Healio provided live coverage of the American Headache Society Annual Meeting in Austin, Texas, where health care professionals gathered for the latest updates on headache disorders.

Migraine has a bidirectional relationship with mental disorders such as anxiety and depression, and one may increase the risk of the other, researchers reported in Cureus.

Lusaris Therapeutics announced its launch with $60 million in Series A financing to advance LSR-1019, a sublingual formulation of 5-MeO-DMT for patients with treatment-resistant depression and other severe neuropsychiatric disorders.

Many patients who experience migraine or headaches either hesitated or never sought medical care for their condition, according to data from two studies presented during the PAINWeek National Conference.

A review published in The Lancet Neurology provides a summary of the classification and management of post-traumatic headache, a “disabling secondary headache disorder” often attributed to traumatic brain injury.

A new advisory board commissioned by the American Headache Society is developing strategies to improve migraine care in primary care offices.